These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 19171800)

  • 1. Accelerated metabolism of voriconazole and its partial reversal by cimetidine.
    Moriyama B; Elinoff J; Danner RL; Gea-Banacloche J; Pennick G; Rinaldi MG; Walsh TJ
    Antimicrob Agents Chemother; 2009 Apr; 53(4):1712-4. PubMed ID: 19171800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of voriconazole metabolism by chloramphenicol in an adolescent with central nervous system aspergillosis.
    Hafner V; Albermann N; Haefeli WE; Ebinger F
    Antimicrob Agents Chemother; 2008 Nov; 52(11):4172-4. PubMed ID: 18794387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes.
    Murayama N; Imai N; Nakane T; Shimizu M; Yamazaki H
    Biochem Pharmacol; 2007 Jun; 73(12):2020-6. PubMed ID: 17433262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring.
    Hassan A; Burhenne J; Riedel KD; Weiss J; Mikus G; Haefeli WE; Czock D
    Ther Drug Monit; 2011 Feb; 33(1):86-93. PubMed ID: 21192313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes.
    Yanni SB; Annaert PP; Augustijns P; Bridges A; Gao Y; Benjamin DK; Thakker DR
    Drug Metab Dispos; 2008 Jun; 36(6):1119-25. PubMed ID: 18362161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Voriconazole.
    Med Lett Drugs Ther; 2002 Jul; 44(1135):63-5. PubMed ID: 12138377
    [No Abstract]   [Full Text] [Related]  

  • 7. [New antifungal agents: voriconazole and caspofungin].
    Dupont B
    Arch Pediatr; 2003 Dec; 10 Suppl 5():592s-598s. PubMed ID: 15022787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole.
    Hyland R; Jones BC; Smith DA
    Drug Metab Dispos; 2003 May; 31(5):540-7. PubMed ID: 12695341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histamine H2-receptor antagonists have no clinically significant effect on the steady-state pharmacokinetics of voriconazole.
    Purkins L; Wood N; Kleinermans D; Nichols D
    Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):51-5. PubMed ID: 14616414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of voriconazole metabolism by rifampin in a patient with acute myeloid leukemia: importance of interdisciplinary communication to prevent treatment errors with complex medications.
    Geist MJ; Egerer G; Burhenne J; Riedel KD; Mikus G
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3455-6. PubMed ID: 17606672
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of voriconazole on tacrolimus metabolism in a kidney transplant recipient.
    Capone D; Tarantino G; Gentile A; Sabbatini M; Polichetti G; Santangelo M; Nappi R; Ciotola A; D'Alessandro V; Renda A; Basile V; Federico S
    J Clin Pharm Ther; 2010 Feb; 35(1):121-4. PubMed ID: 20175821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical importance of the CYP2C19*17 variant allele for voriconazole.
    Dolton MJ; McLachlan AJ
    Br J Clin Pharmacol; 2011 Jan; 71(1):137-8. PubMed ID: 21143511
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of voriconazole and other azole antifungal agents on CYP3A activity and metabolism of tacrolimus in human liver microsomes.
    Zhang S; Pillai VC; Mada SR; Strom S; Venkataramanan R
    Xenobiotica; 2012 May; 42(5):409-16. PubMed ID: 22106961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia.
    Gambillara E; Laffitte E; Widmer N; Decosterd LA; Duchosal MA; Kovacsovics T; Panizzon RG
    Dermatology; 2005; 211(4):363-5. PubMed ID: 16286749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
    Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
    Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distribution of voriconazole in seven body fluids of adult horses after repeated oral dosing.
    Passler NH; Chan HM; Stewart AJ; Duran SH; Welles EG; Lin HC; Ravis WR
    J Vet Pharmacol Ther; 2010 Feb; 33(1):35-41. PubMed ID: 20444023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Voriconazole therapeutic drug monitoring: focus on safety.
    Pasqualotto AC; Xavier MO; Andreolla HF; Linden R
    Expert Opin Drug Saf; 2010 Jan; 9(1):125-37. PubMed ID: 20021293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Voriconazole: in the treatment of invasive aspergillosis.
    Muijsers RB; Goa KL; Scott LJ
    Drugs; 2002; 62(18):2655-64; discussion 2665-6. PubMed ID: 12466006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.
    Prescrire Int; 2004 Feb; 13(69):13-6. PubMed ID: 15055210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steady-state pharmacokinetics and metabolism of voriconazole in patients.
    Geist MJ; Egerer G; Burhenne J; Riedel KD; Weiss J; Mikus G
    J Antimicrob Chemother; 2013 Nov; 68(11):2592-9. PubMed ID: 23766489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.